Akanda (AKAN) Competitors $1.29 -0.04 (-3.01%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.34 +0.05 (+3.88%) As of 07/15/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. LIXT, RNAZ, MBRX, CELZ, SLXN, AIM, OMGA, APLM, CDIO, and BFRIShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Lixte Biotechnology (LIXT), TransCode Therapeutics (RNAZ), Moleculin Biotech (MBRX), Creative Medical Technology (CELZ), Silexion Therapeutics (SLXN), AIM ImmunoTech (AIM), Omega Therapeutics (OMGA), Apollomics (APLM), Cardio Diagnostics (CDIO), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Its Competitors Lixte Biotechnology TransCode Therapeutics Moleculin Biotech Creative Medical Technology Silexion Therapeutics AIM ImmunoTech Omega Therapeutics Apollomics Cardio Diagnostics Biofrontera Akanda (NASDAQ:AKAN) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability. Does the media favor AKAN or LIXT? In the previous week, Lixte Biotechnology had 5 more articles in the media than Akanda. MarketBeat recorded 8 mentions for Lixte Biotechnology and 3 mentions for Akanda. Akanda's average media sentiment score of 0.47 beat Lixte Biotechnology's score of 0.35 indicating that Akanda is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akanda 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lixte Biotechnology 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, AKAN or LIXT? Akanda has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Which has stronger earnings and valuation, AKAN or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkanda$840K2.20-$4.10MN/AN/ALixte BiotechnologyN/AN/A-$3.59M-$1.45-2.56 Do insiders and institutionals believe in AKAN or LIXT? 1.0% of Akanda shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 20.4% of Akanda shares are held by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is AKAN or LIXT more profitable? Company Net Margins Return on Equity Return on Assets AkandaN/A N/A N/A Lixte Biotechnology N/A N/A -189.35% SummaryAkanda beats Lixte Biotechnology on 5 of the 8 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.90M$10.37B$5.62B$9.30BDividend YieldN/A2.09%4.25%4.03%P/E RatioN/A16.6928.5719.58Price / Sales2.2029.09423.3593.43Price / CashN/A22.6736.0257.93Price / Book0.433.598.135.54Net Income-$4.10M$233.40M$3.24B$257.73M7 Day Performance-4.44%-3.21%0.16%-0.08%1 Month Performance0.78%1.23%5.95%8.09%1 Year Performance-71.21%-19.76%26.09%13.02% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkanda0.7495 of 5 stars$1.29-3.0%N/A-71.6%$1.90M$840K0.00110Gap UpLIXTLixte Biotechnology0.244 of 5 stars$2.72+21.4%N/A+53.9%$7.29MN/A-1.884Gap UpRNAZTransCode Therapeutics2.7282 of 5 stars$8.72+8.3%$280.00+3,111.0%-100.0%$7.26MN/A0.009MBRXMoleculin Biotech2.9797 of 5 stars$0.51+31.1%$4.00+684.8%-85.1%$7.20MN/A0.0020Positive NewsGap UpHigh Trading VolumeCELZCreative Medical Technology0.7958 of 5 stars$2.73+2.8%N/A-31.4%$7.06M$10K-0.725SLXNSilexion TherapeuticsN/A$0.81-1.1%$5.00+521.1%N/A$7.00MN/A0.00N/AAIMAIM ImmunoTech1.1108 of 5 stars$9.13+3.2%$275.00+2,912.0%-78.1%$6.98M$146K-19.4320Gap UpOMGAOmega TherapeuticsN/A$0.13-21.8%$8.50+6,700.0%N/A$6.92M$8.10M-0.09120Gap UpAPLMApollomics0.6946 of 5 stars$6.27-2.7%N/A-69.8%$6.91MN/A0.0045Gap DownCDIOCardio Diagnostics3.1191 of 5 stars$3.95+4.2%$60.00+1,419.0%-70.6%$6.87M$19.90K0.001BFRIBiofrontera3.0165 of 5 stars$0.73+4.5%$2.75+278.8%-23.4%$6.86M$38.00M-0.3270 Related Companies and Tools Related Companies LIXT Competitors RNAZ Competitors MBRX Competitors CELZ Competitors SLXN Competitors AIM Competitors OMGA Competitors APLM Competitors CDIO Competitors BFRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKAN Stock Alerts